HBAN vs RAPP · P/E 13, rev $1.56B vs rev $20.0M
Huntington Bancshares Incorporated (HBAN) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
HBAN currently screens at market cap $25.55B and trailing P/E 13.5. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the HBAN and RAPP stock pages for the full models.
Not investment advice.